Ten-year experience with acenocoumarol treatment in an ambulatory cohort of Spanish patients.

Autor: Trullas-Vila JC; Internal Medicine Service, Hospital Sant Jaume, Mulleras, 15-17800, Olot, Girona, Spain. 34944jtv@comb.es, Bisbe-Company J, Freitas-Ramírez A, Soler-Simon S, Bisbe-Company V, Roncero-Vidal JM, Gispert-Magarolas R
Jazyk: angličtina
Zdroj: Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2009 Nov; Vol. 28 (4), pp. 436-43. Date of Electronic Publication: 2009 Feb 19.
DOI: 10.1007/s11239-009-0311-9
Abstrakt: Objective: To analyse incidence of hemorrhagic and thrombotic events in a series of ambulatory patients receiving acenocoumarol in a rural area of Spain (1997-2007).
Results: Out of 1,544 patients, 1,086 are receiving acenocoumarol at present (2% of our region's population). The total follow-up was 5,462 patients-years. Median age was 74 years. INR therapeutic range was 2.0-3.0 in 82.5%. Atrial fibrillation (AF) was the most frequent indication (73%). Incidence of hemorrhagic and thrombotic events was 2.27 and 0.2/100 patients-year, respectively. Gastrointestinal tract was the most frequent site of bleeding. In multivariate analysis, patients with AF and prosthetic heart valves (PHV) had increased risk of bleeding (OR 2.1 and 4.8, respectively). Age and therapeutic ranges of INR were not associated with increased risk of bleeding.
Conclusions: 2% of our population is receiving acenocoumarol. Incidence of hemorrhagic and thrombotic events was low. Patients with AF and PHV had increased risk of bleeding.
Databáze: MEDLINE
Externí odkaz: